ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 11, 2017
Three Notable Pending FDA Approvals
Image Source: Brandon Giesbrecht. The final step of the drug approval process is the filing of a new drug application (NDA), when the FDA assesses trial results before deciding if the treatment warrants marketing approval. A delay or rejection can have a meaningful impact on the equity price, so let’s dig into a few notable upcoming decisions.
Feb 18, 2017
Johnson & Johnson's Oncology Division A Force to Be Reckoned With
Image Source: Open Grid Scheduler. Healthcare and consumer staples giant Johnson & Johnson is a core holding in both newsletter portfolios. Let’s take a deep dive into one of its key sources of growth, its ‘Pharmaceutical’ segment.
Feb 15, 2017
Gilead Sciences Continues Its Meltdown
Image Source: Gilead. Valuentum has been out of Gilead in the newsletter portfolios for some time. As the Best Ideas Newsletter portfolio continues to make new highs, Gilead continues to set new 52-week lows. This is the power of “portfolio thinking,” something we've been preaching for a long time.
Jan 23, 2017
Novartis’ Continuous Dividend Growth and Promising Pipeline
Image Shown: Novartis’ dividend history, source: Novartis. Novartis may be in the penalty box, but a healthy dividend growth track record and a promising pipeline may be difficult to overlook. Let’s dig in.
Jan 19, 2017
The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years.
Sep 24, 2016
Update on Teva and the Generics Market
Image Source: Teva. Best Ideas Newsletter portfolio holding has completed a major acquisition, further strengthening its position in the global generics market, and it expects the generics market to continue expanding at a solid rate.
Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late.
May 10, 2016
Big Pharma 1Q Earnings Roundup, Part I
Image Source: Rodrigo. Let’s take a look at the performance of some of the biggest pharmaceutical companies on the market today. In this article: AZN, ABT, BIIB, LLY, GSK, VRTX, ZTS.
Mar 2, 2016
Politics and the Markets
Image Source: DonkeyHotey. Inside: "The impact of the election of 2016 will be disruptive with wide-ranging implications on several key industries: defense contractors via the trajectory of defense spending, fast-food restaurants and big box retailers via minimum-wage legislation and arguably immigration reform, biotech via wide-spread opposition to existing exorbitant drug prices, healthcare via the pledges of several candidates to repeal Obamacare, insurance given the call for increasing competition between states, and implications on consumer spending given each candidate’s proposed tax plans."
Feb 21, 2016
Growing Cautious on Teva Pharma
Best Ideas Newsletter portfolio holding Teva Pharmaceuticals reported a disappointing fourth quarter.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.